Mikan (Amikacin)

• Amikacin is an aminoglycoside antibiotic used to treat infections caused by Gram‑negative bacteria.
• Severe Gram‑negative bacterial infections: provides bactericidal activity to eradicate the pathogen.
• Sepsis: rapidly reduces bacterial load in systemic infection.
• Hospital‑acquired pneumonia: targets resistant Gram‑negative organisms in the lungs.
• Complicated urinary tract infections: eliminates causative bacteria in the urinary system.
• Intra‑abdominal infections: treats polymicrobial Gram‑negative infections within the abdominal cavity.

• Amikacin binds to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. This disruption leads to bacterial cell death, particularly against aerobic Gram‑negative organisms, and contributes to its rapid bactericidal effect in severe infections.

Amikacin may cause a range of adverse reactions, from mild to severe, depending on patient factors and duration of therapy.

Common Side Effects

• Ototoxicity: hearing loss or tinnitus.
• Nephrotoxicity: elevated serum creatinine or reduced urine output.
• Vestibular dysfunction: dizziness or balance disturbances.
• Injection site reactions: pain, erythema, or swelling.
• Rash or mild skin eruptions.
• Nausea or vomiting.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Respiratory failure: difficulty breathing or respiratory depression.
• Neuromuscular blockade: muscle weakness, especially in patients with myasthenia gravis.
• Severe renal impairment: acute kidney injury requiring dialysis.
• Permanent hearing loss: irreversible auditory damage.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

• Before initiating amikacin therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters.
• Renal function monitoring: check serum creatinine and urine output regularly.
• Hearing assessment: perform baseline and periodic audiometry.
• Dose adjustment in renal impairment: modify dose according to glomerular filtration rate.
• Pregnancy caution: avoid unless benefits outweigh risks (Category D).
• Avoid in patients with known neuromuscular disorders: risk of blockade.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amikacin can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid)

• Concurrent nephrotoxic agents (e.g., vancomycin, amphotericin B): increase risk of kidney injury.
• Loop diuretics (e.g., furosemide): potentiate nephrotoxicity.
• Other aminoglycosides: additive ototoxic and nephrotoxic effects.
• Neuromuscular blocking agents (e.g., succinylcholine): enhance muscle weakness.
• High-dose penicillins: may reduce antibacterial activity.

Moderate Interactions (Monitor Closely)

• NSAIDs: may modestly increase renal risk.
• Diuretics (thiazides): require renal function checks.
• Ototoxic drugs (e.g., loop diuretics, cisplatin): monitor hearing.
• Antacids containing magnesium or aluminum: may affect absorption if oral form used.
• Rifampin: may reduce serum concentrations.